Clinical and economic burdens experienced by patients with painful diabetic peripheral neuropathy: An observational study using a Japanese claims database

Ebata-Kogure, Nozomi; Nozawa, Kazutaka; Murakami, Aya; Toyoda, Tetsumi; Haga, Yuri; Fujii, Koichi

doi:10.1371/journal.pone.0187250

Cited by 19 publications

(17 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The database covers claims from April 2008 until October 2016. This database has been widely used for similar investigations, including those that describe the actual treatment status for a particular disease in Japan [24][25][26][27].…”

Section: Data Sourcementioning

confidence: 99%

Current Status of Helicobacter pylori Diagnosis and Eradication Therapy in Japan Using a Nationwide Database

2019

View full text Add to dashboard Cite

Background: Helicobacter pylori infection increases the risk of stomach cancer; therefore, eradication therapy is recommended for infected individuals. Although several methods are recommended for the diagnosis and therapy of H. pylori infection, their frequency and effectiveness have not been fully investigated in Japan. Methods: A nationwide claims database including > 1.6 million patients (April 2008 -October 2016) in Japan was utilized. We analyzed the distribution of methods for H. pylori diagnosis and therapy, waiting period between eradication and diagnostic test, and success rate of primary therapy. Results: Data for 481,041 patients were extracted. After primary eradication therapy, urea breath test was used for > 80% of diagnoses, and antibody measurement for 0.7%. The success rate of primary eradication was > 80% for most diagnostic methods and 69.0% for antibody measurement; inappropriately-timed antibody measurement may have contributed to this disparity. The overall success rate of eradication therapy decreased from 2011 to 2014, but increased from 2015, coinciding with launch of the potassium-competitive acid blocker vonopra-zan, which showed a higher success rate of eradication than proton-pump inhibitors. Conclusions: Diagnostic tests of H. pylori infection mostly followed Japanese Society for Helicobacter Research guidance, although some antibody measurements were timed inappropriately. Vonoprazan appears to increase the success rate of primary therapy.

show abstract

Section: Data Sourcementioning

confidence: 99%

Current Status of Helicobacter pylori Diagnosis and Eradication Therapy in Japan Using a Nationwide Database

2019

View full text Add to dashboard Cite

show abstract

“…Furthermore, DPN is closely related to alterations in brain structure, especially a reduction in peripheral grey matter volume, which may be responsible for walking disabilities [ 2 , 3 ]. Therefore, patients with DPN may be presented with an impaired quality of life and burdened with high costs of diabetes care [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients

Zhao

Zhang

et al. 2018

Cardiovasc Diabetol

View full text Add to dashboard Cite

BackgroundDiabetic complications may be associated with impaired time-dependent glycemic control. Therefore, long-term glycemic variability, assessed by variations in haemoglobin A1c (HbA1c), may be a potential risk factor for microvascular complications, such as diabetic peripheral neuropathy (DPN). We investigated the association of HbA1c variability with DPN in patients with type 2 diabetes.MethodsIn this cross-sectional study, 563 type 2 diabetic patients who had been screened for DPN and undergone quarterly HbA1c measurements during the year preceding enrolment were recruited. DPN was confirmed in patients displaying both clinical manifestations of neuropathy and abnormalities in a nerve conduction evaluation. HbA1c variability was assessed by the coefficient of variation of HbA1c (CV-HbA1c), and the mean of HbA1c (M-HbA1c) was calculated. In addition, medical history and clinical data were collected.ResultsAmong the recruited patients, 18.1% (n = 102) were found to have DPN, and these patients also presented with a higher CV-HbA1c than the patients without DPN (p < 0.001). The proportion of patients with DPN increased significantly from 6.9% in the first to 19.1% in the second and 28.5% in the third tertile of CV-HbA1c (p for trend < 0.001). After adjusting for initial HbA1c, M-HbA1c and other clinical factors via multiple logistic regression analysis, the odds ratios (ORs) for DPN in the second and third versus those in the first CV-HbA1c tertile were 3.61 (95% CI 1.62–8.04) and 6.48 (2.86–14.72), respectively. The area under the receiver operating characteristic (ROC) curve of CV-HbA1c was larger than that of M-HbA1c, at 0.711 (95% CI 0.659–0.763) and 0.662 (0.604–0.721), respectively. ROC analysis also revealed that the optimal cutoff value of CV-HbA1c to indicate DPN was 15.15%, and its corresponding sensitivity and specificity were 66.67% and 65.73%, respectively.ConclusionsIncreased HbA1c variability is closely associated with DPN in type 2 diabetic patients and could be considered as a potent indicator for DPN in these patients.

show abstract

“…The symptoms of DPNP are commonly described as burning, shooting, tingling, and 'pins and needles', and most patients report moderate or severe levels of pain [7,8]. Individuals with DPNP have been reported to bear greater clinical and economic burdens compared with those with non-painful neuropathy [7,9]. DPNP is commonly associated with insomnia, mood disorders, and worsened quality of life (QOL) [3,6], and has also been shown to be an independent predictor of depression [10].…”

Section: Introductionmentioning

confidence: 99%

Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study

et al. 2020

View full text Add to dashboard Cite

Introduction: Almost one-quarter of Asian patients with diabetes experience diabetic peripheral neuropathic pain (DPNP), which may be associated with moderate or severe levels of pain, insomnia, mood disorders, and worsened quality of life. Current treatments are generally ineffective and may be poorly tolerated. We evaluated mirogabalin as a treatment for DPNP in Asian subjects. Methods: This phase 2, randomized, doubleblind, controlled study was conducted in Japan, Enhanced Digital Features To view enhanced digital features for this article go to https://doi.org/10.6084/ m9.figshare.11698323.

show abstract

Clinical and economic burdens experienced by patients with painful diabetic peripheral neuropathy: An observational study using a Japanese claims database

Cited by 19 publications

References 28 publications

Current Status of Helicobacter pylori Diagnosis and Eradication Therapy in Japan Using a Nationwide Database

Current Status of Helicobacter pylori Diagnosis and Eradication Therapy in Japan Using a Nationwide Database

HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients

Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study

Contact Info

Product

Resources

About